Zidesamtinib - CanMED: HCPCS

Return Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Zidesamtinib

Brand Name:

Jideytro

Strength:

25mg, 100mg

HCPCS:

N/A

SEER*Rx Category:

Chemotherapy

Major Drug Class:

Tyrosine Kinase Inhibitor

Minor Drug Class:

ROS1, ALK, TRK

Oral (Y/N):

Yes

FDA Approval Year:

2026

FDA Discontinuation Year:

CMS Effective Date:

CMS Discontinuation Date:

Status:

In Use